麦澜德(688273) - 投资者关系活动记录表

Group 1: Financial Performance - The company's Q3 2024 revenue reached 1.02 billion CNY, representing a year-on-year increase of 18.75% [1] - The net profit attributable to shareholders for Q3 2024 was 23.46 million CNY, a decrease of 9.39% year-on-year [1] - The net profit after deducting non-recurring items was 22.35 million CNY, showing a slight increase of 0.46% year-on-year [1] - For the first three quarters of 2024, the revenue was 3.31 billion CNY, with a year-on-year growth of 13.81% [2] - The net profit attributable to shareholders for the first three quarters was 96.07 million CNY, reflecting a year-on-year increase of 13.37% [2] - The net profit after deducting non-recurring items for the first three quarters was 88.41 million CNY, with a year-on-year growth of 22.81% [2] Group 2: Strategic Development - The company is focusing on both consumer healthcare and serious medical fields, aiming for innovation and development in pelvic floor rehabilitation [2][3] - The market for pelvic floor dysfunction (PFD) treatment is expanding, with increasing demand for clinical rehabilitation medical devices [3] - The company has launched a new intelligent diagnosis and treatment system, PI-ONE, to enhance its market position in pelvic floor rehabilitation [3] - The company plans to continue expanding into "more serious" and "more consumer" healthcare sectors to seek new growth points [3][4] Group 3: Investor Relations and Future Outlook - The company is considering stock buybacks and equity incentives to enhance shareholder value [4] - There are concerns regarding the company's ability to break through its profit bottleneck, with a focus on optimizing operations and improving efficiency [4] - The company acknowledges the competitive landscape in the consumer healthcare sector but emphasizes its commitment to innovation and maintaining a competitive edge [3][4] Group 4: Risk Warning - Any forecasts or strategic plans mentioned should not be interpreted as commitments or guarantees regarding the company's future performance [4]